18F-AV-1451 positron emission tomography in Alzheimer’s disease and progressive supranuclear palsy

Brain

Volumn 140, Issue 3, 2017, Pages 781-791

  Passamonti, Luca ^a,b   Rodríguez, Patricia Vázquez ^b   Hong, Young T ^b   Allinson, Kieren S J ^c   Williamson, David ^b   Borchert, Robin J ^b   Sami, Saber ^b   Cope, Thomas E ^b   Bevan Jones, W Richard ^b   Jones, P Simon ^b   Arnold, Robert ^b   Surendranathan, Ajenthan ^b   Mak, Elijah ^b   Su, Li ^b   Fryer, Tim D ^b   Aigbirhio, Franklin I ^b   O’Brien, John T ^b   Rowe, James B ^b,d  

^a INSTITUTE OF MOLECULAR BIOIMAGING AND PHYSIOLOGY   (Italy)

^b UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^c CAMBRIDGE UNIVERSITY HOSPITALS NHS FOUNDATION TRUST   (United Kingdom)

^d MEDICAL RESEARCH COUNCIL   (United Kingdom)

Author keywords

Alzheimer s disease; Neurodegeneration; Progressive supranuclear palsy; Tau

Indexed keywords

AMYLOID BETA PROTEIN; FLORTAUCIPIR F 18; NEUROMELANIN; TAU PROTEIN; 7-(6-FLUOROPYRIDIN-3-YL)-5H-PYRIDO(4,3-B)INDOLE; CARBOLINE DERIVATIVE; FLUORODEOXYGLUCOSE F 18; PROTEIN BINDING;

ADDENBROOKES COGNITIVE EXAMINATION; ADULT; AGED; ALZHEIMER DISEASE; ARTICLE; AUTORADIOGRAPHY; BASAL GANGLION; BRAIN TISSUE; CEREBELLUM; CLINICAL ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; DEMENTIA ASSESSMENT; DENTATE NUCLEUS; DIAGNOSTIC ACCURACY; DISEASE EXACERBATION; DISEASE SEVERITY; DRUG BINDING; FEMALE; FRONTAL BONE; FRONTAL CORTEX; GLOBUS PALLIDUS; HIPPOCAMPUS; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN VIVO STUDY; MALE; MEDIAL TEMPORAL LOBE; MESENCEPHALON; MINI MENTAL STATE EXAMINATION; NEUROIMAGING; OCCIPITAL BONE; PARIETAL BONE; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROGRESSIVE SUPRANUCLEAR PALSY; PUTAMEN; RADIOACTIVITY; RISK FACTOR; SUPPORT VECTOR MACHINE; THALAMUS; VERY ELDERLY; AUTOPSY; BRAIN; CASE CONTROL STUDY; COGNITION DISORDERS; COMPLICATION; DIAGNOSTIC IMAGING; DRUG EFFECTS; METABOLISM; MIDDLE AGED; NEUROPSYCHOLOGICAL TEST; NUCLEAR MAGNETIC RESONANCE IMAGING; PROCEDURES; PSYCHOLOGICAL RATING SCALE;

AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; AUTOPSY; AUTORADIOGRAPHY; BRAIN; CARBOLINES; CASE-CONTROL STUDIES; COGNITION DISORDERS; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; NEUROPSYCHOLOGICAL TESTS; POSITRON-EMISSION TOMOGRAPHY; PROTEIN BINDING; PSYCHIATRIC STATUS RATING SCALES; SUPRANUCLEAR PALSY, PROGRESSIVE; TAU PROTEINS;

EID: 85020004576     PISSN: 00068950     EISSN: 14602156     Source Type: Journal    
DOI: 10.1093/brain/aww340     Document Type: Article

References (51)

1. Alexander SK, Rittman T, Xuereb JH, Bak TH, Hodges JR, Rowe JB. Validation of the new consensus criteria for the diagnosis of corticobasal degeneration. J Neurol Neurosurg Psychiatry 2014; 85: 925–9.
2. Anderson JM, Hampton DW, Patani R, Pryce G, Crowther RA, Reynolds R, et al. Abnormally phosphorylated tau is associated with neuronal and axonal loss in experimental autoimmune enceph-alomyelitis and multiple sclerosis. Brain 2008; 131: 1736–48.
3. Ballatore C, Lee VM-Y, Trojanowski JQ. Tau-mediated neurodegeneration in Alzheimer’s disease and related disorders. Nat Rev Neurosci 2007; 8: 663–72.
4. Bevan-Jones RW, Surendranathan A, Passamonti L, Vázquez-Rodríguez P, Arnold R, Mak E, et al. Neuroimaging of inflammation in memory and related other disorders (NIMROD) study protocol: a deep phenotyping cohort study of the role of brain inflammation in dementia, depression and other neurological illnesses. BMJ Open 2016a, in press. doi: 10.1136/bmjopen-2016-013187.
5. 18F]AV-1451 PET in behavioral variant frontotemporal dementia due to MAPT mutation. Ann Clin Transl Neurol 2016; 3: 940–7.
6. 18F- AV1451 PET imaging in semantic dementia. J Neurochem 2016c; 138: 401.
7. Bloom GS. Amyloid-b and tau: the trigger and bullet in Alzheimer disease pathogenesis. JAMA Neurol 2014; 71: 505–8.
8. Braak H, Braak E. Staging of alzheimer’s disease-related neurofibrillary changes. Neurobiol Aging 1995; 16: 271–278.
9. Braak H, Alafuzoff I, Arzberger T, Kretzschmar H, Del Tredici K. Staging of Alzheimer disease-associated neurofibrillary pathology using paraffin sections and immunocytochemistry. Acta Neuropathol 2006; 112: 389–404.
10. Buée L, Delacourte A. Comparative biochemistry of tau in progressive supranuclear palsy, corticobasal degeneration, FTDP-17 and Pick’s disease. Brain Pathol 1999; 9: 681–93.
11. Chien DT, Bahri S, Szardenings AK, Walsh JC, Mu F, Su M-Y, et al. Early clinical PET imaging results with the novel PHF-tau radioli-gand [F-18]-T807. J. Alzheimers Dis 2013; 34: 457–68.
12. Clavaguera F, Akatsu H, Fraser G, Crowther RA, Frank S, Hench J, et al. Brain homogenates from human tauopathies induce tau inclusions in mouse brain. Proc Natl Acad Sci USA 2013; 110: 9535–40.
13. Cortes C, Vapnik V. Support-vector networks. Mach Learn 1995; 20: 273–97.
14. de Calignon A, Polydoro M, Suárez-Calvet M, William C, Adamowicz DH, Kopeikina KJ, et al. Propagation of Tau pathology in a model of early Alzheimer’s disease. Neuron 2012; 73: 685–97.
15. Dickson DW, Rademakers R, Hutton ML. progressive supranuclear palsy: pathology and genetics. Brain Pathol 2007; 17: 74–82.
16. Dickson DW, Ahmed Z, Algom AA, Tsuboi Y, Josephs KA. Neuropathology of variants of progressive supranuclear palsy. Curr Opin Neurol 2010; 23: 394–400.
17. Espinoza M, de Silva R, Dickson DW, Davies P. Differential Incorporation of Tau Isoforms in Alzheimer’s disease. J Alzheimers Dis 2008; 14: 1–16.
18. Fernández-Nogales M, Cabrera JR, Santos-Galindo M, Hoozemans JJM, Ferrer I, Rozemuller AJM, et al. Huntington’s disease is a four-repeat tauopathy with tau nuclear rods. Nat Med 2014; 20: 881–5.
19. Goedert M, Wischik CM, Crowther RA, Walker JE, Klug A. Cloning and sequencing of the cDNA encoding a core protein of the paired helical filament of Alzheimer disease: identification as the microtu-bule-associated protein tau. Proc Natl Acad Sci USA 1988; 85: 4051–5.
20. Golbe LI, Ohman-Strickland PA. A clinical rating scale for progressive supranuclear palsy. Brain 2007; 130: 1552–65.
21. Gunn RN, Lammertsma AA, Hume SP, Cunningham VJ. Parametric imaging of ligand-receptor binding in PET using a simplified reference region model. Neuroimage 1997; 6: 279–87.
22. Hammers A, Allom R, Koepp MJ, Free SL, Myers R, Lemieux L, et al. Three-dimensional maximum probability atlas of the human brain, with particular reference to the temporal lobe. Hum Brain Mapp 2003; 19: 224–47.
23. Hansen AK, Knudsen K, Lillethorup TP, Landau AM, Parbo P, Fedorova T, et al. In vivo imaging of neuromelanin in Parkinson’s disease using 18F-AV-1451 PET. Brain 2016; 139: 2039–49.
24. Hatashita S, Yamasaki H. Clinically different stages of Alzheimer’s disease associated by amyloid deposition with [11C]-PIB PET imaging. J. Alzheimers Dis 2010; 21: 995–1003.
25. Hatashita S, Yamasaki H. Diagnosed mild cognitive impairment due to Alzheimer’s disease with PET biomarkers of beta amyloid and neuronal dysfunction. PLoS One 2013; 8: e66877
26. Hauw JJ, Daniel SE, Dickson D, Horoupian DS, Jellinger K, Lantos PL, et al. Preliminary NINDS neuropathologic criteria for Steele-Richardson-Olszewski syndrome (progressive supranuclear palsy). Neurology 1994; 44: 2015–19.
27. Hodges JR, Davies RR, Xuereb JH, Casey B, Broe M, Bak TH, et al. Clinicopathological correlates in frontotemporal dementia. Ann Neurol 2004; 56: 399–406.
28. Irwin DJ, Lee VM-Y, Trojanowski JQ. Parkinson’s disease dementia: convergence of a-synuclein, tau and amyloid-b pathologies. Nat Rev Neurosci 2013; 14: 626–36.
29. Johnson KA, Schultz A, Betensky RA, Becker JA, Sepulcre J, Rentz D, et al. Tau PET imaging in aging and early Alzheimer’s disease. Ann Neurol 2016; 79: 110–19.
30. Kinahan PE, Rogers JG. Analytic 3D image reconstruction using all detected events. IEEE Trans Nucl Sci 1989; 36: 964–8.
31. Litvan I, Agid Y, Calne D, Campbell G, Dubois B, Duvoisin RC, et al. Clinical research criteria for the diagnosis of progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome): report of the NINDS-SPSP international workshop. Neurology 1996a; 47: 1–9.
32. Litvan I, Hauw JJ, Bartko JJ, Lantos PL, Daniel SE, Horoupian DS, et al. Validity and reliability of the preliminary NINDS neuropathologic criteria for progressive supranuclear palsy and related disorders. J Neuropathol Exp Neurol 1996b; 55: 97–105.
33. Litvan I, Lees PSJ, Cunningham CR, Rai SN, Cambon AC, Standaert DG, et al. Environmental and occupational risk factors for progressive supranuclear palsy: case-control study. Mov Disord 2016; 31: 644–52.
34. Marquié M, Normandin MD, Vanderburg CR, Costantino IM, Bien EA, Rycyna LG, et al. Validating novel tau positron emission tomography tracer [F-18]-AV-1451 (T807) on postmortem brain tissue. Ann Neurol 2015; 78: 787–800.
35. Maruyama M, Shimada H, Suhara T, Shinotoh H, Ji B, Maeda J, et al. Imaging of Tau pathology in a tauopathy mouse model and in Alzheimer patients compared to normal controls. Neuron 2013; 79: 1094–108.
36. McKhann GM, Knopman DS, Chertkow H, Hyman BT, Jack CR, Kawas CH, et al. The diagnosis of dementia due to Alzheimer’s disease: recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimers Dement 2011; 7: 263–9.
37. Murray ME, Kouri N, Lin W-L, Jack CR, Dickson DW, Vemuri P. Clinicopathologic assessment and imaging of tauopathies in neurodegenerative dementias. Alzheimers Res Ther 2014; 6: 1.
38. Okamura N, Furumoto S, Fodero-Tavoletti MT, Mulligan RS, Harada R, Yates P, et al. Non-invasive assessment of Alzheimer’s disease neurofibrillary pathology using 18F-THK5105 PET. Brain 2014; 137: 1762–71.
39. Okello A, Koivunen J, Edison P, Archer HA, Turkheimer FE, Någren K, et al. Conversion of amyloid positive and negative MCI to AD over 3 years. Neurology 2009; 73: 754–60.
40. Ossenkoppele R, Schonhaut DR, Baker SL, O’Neil JP, Janabi M, Ghosh PM, et al. Tau, Amyloid, and Hypometabolism in a Patient with Posterior Cortical Atrophy. Ann Neurol 2015; 77: 338–42.
41. Ossenkoppele R, Schonhaut DR, Schöll M, Lockhart SN, Ayakta N, Baker SL, et al. Tau PET patterns mirror clinical and neuroanatomical variability in Alzheimer’s disease. Brain 2016; 139: 1551–67.
42. Petersen RC, Smith GE, Waring SC, Ivnik RJ, Tangalos EG, Kokmen E. Mild cognitive impairment: clinical characterization and outcome. Arch Neurol 1999; 56: 303–8.
43. Schofield EC, Caine D, Kril JJ, Cordato NJ, Halliday GM. Staging disease severity in movement disorder tauopathies: brain atrophy separates progressive supranuclear palsy from corticobasal degeneration. Mov Disord 2005; 20: 34–9.
44. Schöll M, Lockhart SN, Schonhaut DR, O’Neil JP, Janabi M, Ossenkoppele R, et al. PET imaging of tau deposition in the aging human brain. Neuron 2016; 89: 971–82.
45. Schwarz AJ, Yu P, Miller BB, Shcherbinin S, Dickson J, Navitsky M, et al. Regional profiles of the candidate tau PET ligand 18F-AV-1451 recapitulate key features of Braak histopathological stages. Brain 2016; 139: 1539–50.
46. Serrano-Pozo A, Frosch MP, Masliah E, Hyman BT. Neuropathological alterations in Alzheimer disease. Cold Spring Harb Perspect Med 2011; 1: a006189.
47. Smith R, Schain M, Nilsson C, Strandberg O, Olsson T, Hägerström D, et al. Increased basal ganglia binding of (18) F-AV-1451 in patients with progressive supranuclear palsy. Mov Disord 2016, in press.
48. Spillantini M, Goedert M. Tau and parkinson disease. JAMA 2001; 286: 2324–6.
49. Williams DR, de Silva R, Paviour DC, Pittman A, Watt HC, Kilford L, et al. Characteristics of two distinct clinical phenotypes in pathologically proven progressive supranuclear palsy: Richardson’s syndrome and PSP-parkinsonism. Brain 2005; 128: 1247–58.
50. Williams DR, Holton JL, Strand C, Pittman A, de Silva R, Lees AJ, et al. Pathological tau burden and distribution distinguishes progressive supranuclear palsy-parkinsonism from Richardson’s syndrome. Brain 2007; 130: 1566–76.
51. Xia C-F, Arteaga J, Chen G, Gangadharmath U, Gomez LF, Kasi D, et al. [(18)F]T807, a novel tau positron emission tomography imaging agent for Alzheimer’s disease. Alzheimers Dement 2013; 9: 666–76.